I agree . And I read a year or two ago ( can't remember if in a PR, filing or a presentation / video transcript) that NWBO used a consulting firm to develop their ECA and NWBO has no invoIvement in it , so it was completely independent . Very stringent measures/ guidelines were used. I am forgetting name of the firm, but I researched at that time and it is a reputable large firm in UK which has worked with MHRA in the past . So they did their due diligence in that respect . But on the same token, if I remember correctly there have been GBM trials which have used patient level data . But I agree that issue should have come up much sooner last year .